Works in a cross functional team including clinician, drug discovery biologist, medicinal chemist to advance novel drug candidates into clinical development.Secured SBIR Phase 1 grant from NIDDK as PI (2019) and Co-PI (Sept 2017).Developed a novel reversible UUO model and screened novel compounds for its antifibrotic effect.Introduced high throughput method of measuring glomerular filtration rate in rodents.Established several animal models of Irritable bowel syndrome, metabolic, liver, cardiovascular and renal injury.Actively performed in-vitro work in renal, hepatic and cardiomyocytes related to drug discovery projects.

• Designed, performed and analyzed novel drug/gene based therapies for cardiovascular disorders. • Responsible for the generation of conditional knock-down of tissue specific klotho mice for investigating cardiovascular disorders (heart failure, Pulmonary Hypertension, Arterial stiffening, hypertension).• Used the highly sensitive Transonic’s admittance technology to measure heart function (pressure volume loop).• Independently mentored postdoctoral fellows, graduate students, summer interns and research technicians.• Major accomplishment at University of Oklahoma HSC include: Bringing innovative surgical concepts to assess reno-cardiovascular disorders. Introduced and established highly reliable PV loop system for heart failure studies. Successfully developed and validated atomic Spectrometer for electrolytes quantification. Awarded “Responsible conduct of research award” by Univ of Oklahoma HSC. Awarded “Dean’s Postdoctoral award” by Univ of Oklahoma HSC.

Demonstrated for the first time that infusion of novel peptide AT2 receptor agonist C21 promotes natriuresis in obese Zucker rats.Development of protocols for in-vivo administration of drugs and urine collection by catheterizing the ureter. Renal function studies (GFR, Renal Blood Flow and Sodium Balance Studies) in conscious and anesthetized rats.Utilized siRNA approach to knock down AT2 receptor in kidney of conscious rats.Utilized telemetry approach to measure blood pressure, heart rate and pulse pressure in obese rats. Actively involved in data collection, analysis and interpretation of results using Data Quest ART analysis software.

• Demonstrated the protective role of Angiotensin II type 2 receptor against kidney injury and hypertension in obese rats.• Established and utilized telemetry approach to measure blood pressure, heart rate and pulse pressure in diabetic mice and obese rats. Actively involved in data collection, analysis and interpretation of results using Data Quest ART analysis software. • Mentored several undergraduate and graduate students.• Major accomplishment at University of Houston include: Established highly sensitive surgical procedure to assess kidney function in conscious and anesthetized rats. Orchestrated the setup of Telemetry system for hypertension studies.